Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress
Executed binding term sheet with Sorrento Therapeutics (NASDAQ:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including DYAI-100, Dyadic's lead COVID-19 vaccine candidateNew collaboration with India's Syngene International to develop a COVID-19 vaccine candidateNew co-development collaboration with South Africa's Rubic consortium to establish a basis for researching, developing, and manufacturing multiple other C1 produced vaccines in addition to DYAI-100Potential to support vaccine production for up to 100% of the world's populationDyadic's C1 productio
